RecruitingPhase 2NCT07025174

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
First Affiliated Hospital of Zhejiang University
Principal Investigator
Tingbo Liang, MD, M.D
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine
Intervention
PD-1/CTLA-4 Dual Functional Antibody(drug)
Enrollment
60 target
Eligibility
18-75 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07025174 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials